
OTCMKTS:RBGLY
Their pharmaceutical division is about 20% of their total revenues. 80% of the business is doing well but 20% is going to suffer a little bit when their big drug comes off patent. Watch the stock and see if there is an entry level a lower price from here. Very good company. Executes extremely well on the products that they have. Margins are high. Dividend growth over time is there.
Is it a good entry point after their big drug goes off-patent? When companies come off patent, it really comes down to the quality of the management team. This company’s management has done a terrific job at growing earnings, cash flow, dividends and sales. Doesn’t think it would be that great a concern that one of their drugs is coming off patent because they can just turned around given that they’ve got more of the consumer product business as a backdrop.
Reckitt Benckiser is a American stock, trading under the symbol RBGLY (previously RBGLY-OTC on Stockchase) on the US OTC (RBGLY). It is usually referred to as OTC:RBGLY or RBGLY
In the last year, there was no coverage of Reckitt Benckiser published on Stockchase.
Reckitt Benckiser was recommended as a Top Pick by David Driscoll on 2012-09-14. Read the latest stock experts ratings for Reckitt Benckiser.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Reckitt Benckiser in the last year. It is a trending stock that is worth watching.
On 2026-05-22, Reckitt Benckiser (RBGLY) stock closed at a price of $12.70.
He recently sold. Sadly, baby died from its high-risk infant formula. $60M judgement. Billions more in lawsuits just waiting in the wings. Asked himself if he'd buy today if not already owned, the answer was no, so he sold.